ISTH 2022 Congress
Fibrinolysis and Proteolysis » Fibrinogen and Factor XIII
Theme Navigation
- ISTH 2022 Congress
- Fibrinolysis and Proteolysis
- Fibrinogen and Factor XIII
- Fibrinolysis and Proteolysis
-
Abstract Number: OC 76.2
A zebrafish model of dysfibrinogenemia caused by hotspot mutations in the human fibrinogen gamma chain
-
Abstract Number: OC 29.1
Both α- and γ-chain crosslinks mediated by FXIIIa affect fibrin fibre resistance to rupture
-
Abstract Number: PB0619
Clot Collapse in Scanning Electron Microscopy (SEM)
-
Abstract Number: OC 76.5
Clot Destabilisation by the Inclusion of Fibrin with Truncations in the αC-region
-
Abstract Number: PB0624
Comparison of fibrinogen concentrates to cryoprecipitate in restoring clot integrity and stability against fibrinolytic degradation
-
Abstract Number: PB0622
Determining the dominant-negative causality of FXIII heterozygous mutations using a bi-cistronic, bi-tagged expression system
-
Abstract Number: OC 29.4
Development of recombinant antibodies targeting the coagulation factor XIII-B subunit for research and therapeutic use
-
Abstract Number: OC 29.5
Dysregulated fibrinogen γ-chain cross-linking in FibγΔ5 mice drives acute liver injury after acetaminophen overdose
-
Abstract Number: OC 46.1
Fibrin Film Formation is Enhanced by Red Blood Cells and Reduces Platelet Spreading
-
Abstract Number: OC 29.3
Fibrinogen αC-Connector is Critical for Fibrin Fiber Assembly and Mechanical Strength
-
Abstract Number: OC 76.1
Functional characterization and structural modeling of DNA-aptamers targeting activated coagulation Factor XIII
-
Abstract Number: PB0620
Low molecular weight heparin slows the formation of clots from patients within twenty-four hours of acute PE
-
Abstract Number: OC 46.2
Neutrophil Cathepsin G Cleaves Fibrinogen Affecting Clot Structure
-
Abstract Number: PB0623
Role of Transglutaminase 2 in Haemostasis and as a Novel Treatment Option for Acquired Autoimmune Factor XIII Deficiency